Psilocybin in AUD and Depression: Cognitive and Clinical Effects in Pilot RCT

Psilocybin Shows Mixed Cognitive and Clinical Outcomes in AUD and Depression

A secondary analysis of a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT04620759) published on October 29, 2026, provides new insights into psilocybin’s effects on cognition and clinical outcomes in patients with co-occurring alcohol use disorder (AUD) and major depressive disorder (MDD). The study, conducted with a small subset (psilocybin n=12, placebo n=13), found that psilocybin slowed task switching but did not consistently enhance cognitive flexibility or willingness to exert cognitive control. Both groups saw reductions in drinking, but these were associated with increased cognitive stability rather than flexibility.

Mechanistic Insights: Cognitive Stability, Flexibility, and Motivation

Psilocybin’s post-acute effects on cognitive control are of growing interest as researchers seek to understand potential transdiagnostic mechanisms underlying psychedelic therapy. In this study, participants completed five cognitive tasks before and approximately one week after dosing. The tasks were designed to assess the continuum from cognitive stability (the ability to maintain focus and resist distraction) to flexibility (the ability to adapt to changing rules or feedback).

Relative to placebo, psilocybin significantly slowed response times in cued task switching (effect sizes d=1.01–1.12, Bayes factors BF10=7.7–17), suggesting a shift toward cognitive stability. However, effects on feedback-driven flexibility measures were inconsistent, and the largest observed effect—reduced practice-related perseveration under psilocybin—was modest (d=-0.79, BF10=1.1). Importantly, the study found no evidence that psilocybin increased the willingness to exert cognitive effort, a key prediction of the motivational (PRISM) account of psychedelic action.

Notably, reductions in drinking were linked to increased cognitive stability (stability composite rho=-0.64, BF10=29), and lower baseline working-memory span predicted greater drinking reduction. However, improvements in depressive symptoms, which were greater in the psilocybin arm (PHQ-9 d=-0.88, BF10=2.7), did not correlate with changes in cognitive measures.

Implications for Research and Policy: Power, Mechanisms, and Treatment Development

This pilot study’s findings have several implications for the design and interpretation of future psychedelic trials targeting AUD, depression, or their co-occurrence. First, the results challenge the assumption that psilocybin’s therapeutic effects are mediated by enhanced cognitive flexibility or increased motivation to exert cognitive control, at least in the subacute period (one week post-dose). Instead, drinking reduction was associated with greater cognitive stability, a finding that may inform both mechanistic models and outcome selection in future studies.

Second, the study underscores the need for adequately powered trials. None of the cognitive effects survived correction for multiple comparisons, and most Bayes factors were inconclusive. This highlights the risk of overinterpreting small-sample exploratory findings—a recurrent issue in early-phase psychedelic research. Regulatory agencies and funding bodies may wish to prioritize larger, mechanistically informed studies that can disentangle direct drug effects from expectancy, practice, and baseline cognitive differences.

Third, the lack of association between cognitive change and depressive symptom improvement suggests that psilocybin’s antidepressant effects may operate independently of the cognitive domains assessed here. This nuance is important for policymakers and clinicians considering the translation of psychedelic-assisted therapy into practice, especially for dual-diagnosis populations.

Risks, Limitations, and Unknowns

The pilot nature of this analysis introduces several limitations. The small sample size (n=25) limits statistical power and generalizability. The cognitive battery may not capture all relevant domains, and the one-week follow-up may miss longer-term or delayed effects. In addition, the study did not detect adverse cognitive effects beyond slowed task switching, but rare or subtle risks cannot be excluded in such a small cohort.

Another non-obvious risk is the potential for cognitive stability to reinforce maladaptive patterns in some individuals, particularly if flexibility is needed for sustained behavior change. This possibility remains speculative but warrants attention in future trials with more granular cognitive and behavioral measures.

Looking Forward: Precision, Power, and Mechanistic Clarity

Future research should prioritize larger, well-powered trials with longitudinal follow-up and multidimensional cognitive assessment to clarify psilocybin’s mechanisms in comorbid AUD and depression. The finding that drinking reduction tracked with cognitive stability, not flexibility, suggests a need to refine mechanistic hypotheses and explore individual differences in baseline cognitive function as moderators of treatment response. As the field moves toward regulatory consideration and clinical implementation, nuanced mechanistic understanding will be crucial to optimize benefit-risk profiles and guide patient selection.

How we research: This briefing was authored by Dr. Alex M. Carter, PhD (Neuroscience), and reviewed by Dr. Jamie Lee, MD, on 2026-11-01. Primary data were obtained directly from the published trial analysis (OpenAlex W7224546654) and the registered protocol (NCT04620759).